Market Research Reports and Industry Reports

UroGen Pharma Ltd (URGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

UroGen Pharma Ltd (UroGen Pharma), formerly TheraCoat Ltd is a biopharmaceutical company that develops uro-oncology drugs and urological pathologies. The companys pipeline products comprise drug candidates for various forms of non-muscle invasive urothelial cancer, including low grade bladder cancer, carcinoma in situ bladder cancer and low grade upper tract urothelial carcinoma. It utilizes proprietary platform technologies such as RTGel, reverse thermal gelation hydrogel for managing formulations of chemotherapy; and immunotherapy technology to develop immune-modulation drug candidates. The company operates in Israel and the US. UroGen Pharma is headquartered in Raanana, Israel.

UroGen Pharma Ltd (URGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
UroGen Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
UroGen Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
UroGen Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
UroGen Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
UroGen Pharma Ltd, Medical Devices Deals, 2011 to YTD 2017 9
UroGen Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
UroGen Pharma Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
TheraCoat to Raise USD20 Million in Venture Financing 11
TheraCoat Raises US$7 Million In Venture Financing 12
Equity Offering 13
UroGen Pharma Raises USD67 Million in IPO 13
UroGen Pharma Ltd - Key Competitors 15
UroGen Pharma Ltd - Key Employees 16
UroGen Pharma Ltd - Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Financial Announcements 18
Nov 14, 2017: UroGen Pharma Reports Third Quarter 2017 Financial Results and Recent Corporate Developments 18
Corporate Communications 19
Nov 02, 2017: UroGen Pharma Appoints Former Kite Pharma Chief Operating Officer Cynthia M. Butitta to its Board of Directors 19
May 16, 2017: UroGen Pharma Appoints Fred E. Cohen, MD, to its Board of Directors 20
Apr 24, 2017: UroGen Pharma Welcomes New Board Member Kate Falberg 21
Feb 09, 2016: UroGen Pharma Strengthens Board of Directors and Senior Management Team 22
Jan 13, 2016: UroGen Pharma Strengthens Leadership Team 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List Of Tables

List of Tables
UroGen Pharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
UroGen Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
UroGen Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
UroGen Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
UroGen Pharma Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
UroGen Pharma Ltd, Medical Devices Deals, 2011 to YTD 2017 9
UroGen Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
TheraCoat to Raise USD20 Million in Venture Financing 11
TheraCoat Raises US$7 Million In Venture Financing 12
UroGen Pharma Raises USD67 Million in IPO 13
UroGen Pharma Ltd, Key Competitors 15
UroGen Pharma Ltd, Key Employees 16
UroGen Pharma Ltd, Subsidiaries 17

UroGen Pharma Ltd (URGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

UroGen Pharma Ltd (UroGen Pharma), formerly TheraCoat Ltd is a biopharmaceutical company that develops uro-oncology drugs and urological pathologies. The companys pipeline products comprise drug candidates for various forms of

USD 250View Report

UroGen Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

UroGen Pharmaceuticals Ltd (UroGen Pharma), formerly TheraCoat Ltd is a biopharmaceutical company that develops uro-oncology drugs and urological pathologies. The companys pipeline products comprise drug candidates for various forms of

USD 250View Report

QRxPharma Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

QRxPharma Ltd (QRxPharma) develops and commercializes treatments for pain management and abuse prevention products. The companys product portfolio includes late and early stage clinical drug candidates. Its dual opioid product

USD 250View Report

iX Biopharma Ltd Strategic Analysis Review- iX Biopharma Ltd SWOT, Outlook, Operations and Financial Profile

iX Biopharma Ltd Company Profile provides strategic analysis of iX Biopharma Ltd Company in current market conditions. The companys business/ operational/growth strategies are analyzed in the unique research work. Growth

USD 200View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Dec 2017
No. of Pages :24
Country :Israel
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube